Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Matt Rourke / AP
Cigna received clearance Friday from the Centers for Medicare and Medicaid Services to start marketing and selling its Medicare Advantage plans again. The federal agency sanctioned Cigna in January 2016 after discovering Cigna inappropriately denied care and prescription drugs to its Medicare Advantage customers.
Why it matters: Medicare Advantage, the private, narrow-network version of Medicare that enrolls almost 20 million seniors and disabled people, is a goldmine for health insurers. It's also a safe investment since the program has bipartisan support and will grow as more baby boomers age. The sanctions cost Cigna more than $500 million, including 107,000 lost Medicare members, but now it can re-enter the program now that the feds deemed the problems were fixed.